During outpatient and inpatient consultations, we often encounter questions about how long after coronary stenting we can actually have surgery. A key treatment after stent implantation is oral antiplatelet drugs to prevent cardiovascular events caused by in-stent thrombosis. According to national and international guidelines, dual antiplatelet drugs should be taken continuously for at least 12 months after drug-eluting stent implantation, and at least 1 month for metal bare stents, preferably 12 months. Therefore, a difficult problem for many patients to circumvent while on medication is the dilemma of elective or urgent non-cardiac surgical procedures: sudden discontinuation of medication increases the risk of thrombosis and non-stopping increases the risk of perioperative bleeding. Relevant national and international guidelines stipulate that clopidogrel should be discontinued for at least 5 days for elective cardiac surgery such as CABG, except for emergency surgery; elective non-cardiac surgery should be postponed as much as possible: metal bare stents preferably after 6 weeks postoperatively, and drug-eluting stents preferably 12 months after implantation. The perioperative antithrombotic regimen is adjusted on the basis of a comprehensive weighing of the bleeding risk of the procedure performed and the risk of coronary ischemia. For low risk of bleeding with aspirin alone, continue; for high risk of bleeding, suspend; for low risk of bleeding with dual antiplatelet therapy, discontinue aspirin and continue clopidogrel; for high risk of bleeding, discontinue both. Procedures with very high risk of bleeding include: neurosurgery (cranial, spinal), major liver surgery; procedures with high risk of bleeding include: vascular surgery and major surgery such as abdominal aortic aneurysm repair, aorto-femoral bypass graft, major abdominal surgery, major lower extremity joint surgery, oral surgery, thoracic surgery lung lobectomy, renal puncture biopsy or colon multi-site biopsy . The specific adjustment plan often requires careful weighing by the interventional cardiologist in conjunction with the surgeon, taking into account the patient’s individual situation and using various evaluation models. A recent study published in the Journal of the American Medical Association (JAMA) provides an initial look at this dilemma. The study included a total of 28,029 patients who underwent stenting and non-cardiac surgery within two weeks, all of whom were divided into four groups according to their surgical time to stenting. percent, 6 weeks to 6 months: 6,4 percent, 12-24 months: 3.5 percent. In terms of the type of stent implanted, the overall cardiovascular event rate was significantly lower in patients implanted with drug stents than with metallic bare stents. In conclusion, the longer the surgical procedure is delayed, the lower the number of cardiovascular events, but the exact length of time must be weighed against the urgency of the surgical procedure and the magnitude of the cardiac risk.